Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in MS Spasticity
NCT01599234Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Mar 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Sativex with Placebo (2 arms). Primary endpoint: Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score at 15 weeks. Started Mar 2005; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01599234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599234.